Impax Labs Inc (IPXL) 31.15 $IPXL What Awaits Aerie

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Impax Labs Inc (IPXL) 31.15 $IPXL

What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report second-quarter 2016 results after the market closes on Aug 3.
IPXL: 31.15 (-0.27), IRWD: 13.94 (-0.19), AERI: 17.18 (-0.17), EXEL: 9.27 (+0.09)

Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:55AM CDT
Exelixis, Inc. (EXEL) is scheduled to report second-quarter 2016 results on Aug 3 after the market closes.
IPXL: 31.15 (-0.27), IRWD: 13.94 (-0.19), EXEL: 9.27 (+0.09)

Aegerion (AEGR): What Awaits for the Stock in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:03AM CDT
Aegerion (AEGR) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 31.15 (-0.27), IRWD: 13.94 (-0.19), AEGR: 1.47 (+0.03), EXEL: 9.27 (+0.09)

Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 4:13PM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 31.15 (-0.27), IRWD: 13.94 (-0.19), KERX: 4.72 (-2.64), EXEL: 9.27 (+0.09)

What's in Store for Prothena (PRTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:44PM CDT
Prothena Corporation plc (PRTA) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 31.15 (-0.27), IRWD: 13.94 (-0.19), PRTA: 56.66 (+1.61), EXEL: 9.27 (+0.09)

Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 31.15 (-0.27), ECYT: 3.18 (unch), IRWD: 13.94 (-0.19), EXEL: 9.27 (+0.09)

Coverage Initiated on Select Healthcare Stocks
ACCESSWIRE - Thu Jul 14, 8:17AM CDT
LONDON, UK / ACCESSWIRE / July 14, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Healthcare sector. Companies recently under review include Shire, Novartis, Anavex Life Sciences, and Impax Laboratories. See our complete notes on Shire at:
IPXL: 31.15 (-0.27), AVXL: 3.61 (-0.23), SHPG: 194.00 (-0.12), NVS: 83.07 (-0.19)

Teva Raises Q2 Guidance; to Unveil 2016-2019 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:47AM CDT
Ahead of its acquisition of Allergan's Generics business, Teva Pharmaceutical (TEVA) raised its second-quarter 2016 guidance for earnings and revenues.
IPXL: 31.15 (-0.27), AGN: 254.86 (+1.91), MYL: 46.74 (-0.05), TEVA: 53.61 (+0.11)

Impax to Report Second Quarter 2016 Results on August 9, 2016
PR Newswire - Thu Jul 07, 7:05AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its second quarter 2016 financial results on Tuesday, August 9, 2016, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on August 9, 2016.
IPXL: 31.15 (-0.27)

Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 31.15 (-0.27), AGN: 254.86 (+1.91), TEVA: 53.61 (+0.11), AMPH: 16.29 (+0.11)

Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Wed Jun 22, 3:33AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Underperform to Neutral at BofA/Merrill today. The stock closed yesterday at $28.31 on volume of 3.0 million shares, above average daily volume of 539,000. Potential upside of 70.4% exists for Impax Laboratories, based on a current level of $28.31 and analysts' average consensus price target of $48.25. Impax Laboratories shares should first meet resistance at the 50-day moving average (MA) of $33.81 and find additional resistance at the 200-day MA of $38.86.
IPXL: 31.15 (-0.27)

United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 254.86 (+1.91), IPXL: 31.15 (-0.27), CP.TO: 195.61 (+0.79), WERN: 24.96 (-0.16), CP: 150.10 (+0.32), ASEI: 36.97 (+0.06), IMPV: 46.40 (-0.72), UAL: 47.36 (+0.47)

Look for Shares of Impax Laboratories to Potentially Rebound after Yesterday's 11.26% Sell Off
Comtex SmarTrend(R) - Tue Jun 21, 3:09PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $28.11 to a high of $30.00. Yesterday, the shares fell 11.3%, which took the trading range below the 3-day low of $31.31 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 31.15 (-0.27)

Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva" and affiliates of Allergan plc ("Allergan" for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA" for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction" for an aggregate purchase price of $586 million.
IPXL: 31.15 (-0.27), AGN: 254.86 (+1.91)

Impax to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 3:10PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 2:40 p.m. Pacific Time. The conference will be held in Rancho Palos Verdes, CA.
IPXL: 31.15 (-0.27)

Impax Labs reports 1Q loss
Automated Insights - Tue May 10, 5:48AM CDT
HAYWARD, Calif. (AP) _ Impax Laboratories Inc. (IPXL) on Tuesday reported a loss of $10.4 million in its first quarter.
IPXL: 31.15 (-0.27)

Impax Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:40AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported first quarter 2016 financial results for the quarter ended March 31, 2016.
IPXL: 31.15 (-0.27)

Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:48AM CDT
A positive Earnings ESP coupled with impressive Zacks Rank has made Impax Laboratories (IPXL) an interesting choice for the investors.
IPXL: 31.15 (-0.27)

Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 31.15 (-0.27), CLSN: 1.22 (-0.01), JAZZ: 150.53 (-0.44)

What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 31.15 (-0.27), CPRX: 0.76 (+0.04), JAZZ: 150.53 (-0.44), XON: 27.38 (+2.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating the Rising Tide of AI-Driven Cyber Threats

Updated Category News Views 118

The Evolving Landscape of Cyber Threats In today's world, artificial intelligence is rapidly changing the nature of cyber threats. Recent studies reveal that a significant number of companies have encountered AI-driven cyberattacks, highlighting a critical gap in their defense strategies. Despite this alarming trend, many organizations are yet to fully embrace AI in their...

Continue Reading
Insight into the Bullish Movements Surrounding DPZ Stock

Updated Category News Views 58

Understanding the Options Dynamics for Domino's Pizza Investors are expressing a clear bullish sentiment towards Domino's Pizza as evident from the recent options market activities. Analyzing the options history for Domino's Pizza (DPZ), we found a total of 10 significant trades. These trades reveal that approximately 50% of traders leaned towards bullish strategies while...

Continue Reading
PDD Holdings Faces Legal Challenges Over Securities Violations

Updated Category News Views 230

PDD Holdings Faces Legal Challenges Over Securities Violations PDD Holdings, Inc. is currently facing a major class action lawsuit. This legal action stems from accusations that the company misled investors about potential compromises to its applications, raising serious concerns about user privacy, particularly regarding unauthorized access to private messages. Details...

Continue Reading
Significant Shareholder Announcement for Kenmare Resources

Updated Category News Views 98

Major Holdings Notification for Kenmare Resources Plc Understanding the dynamics of major shareholdings is essential for investors and stakeholders alike. Kenmare Resources Plc has recently updated the market regarding key holdings that affect its share structure. The notification process is transparent, with clear communication ensuring that all relevant details are...

Continue Reading
Exploring High-Yield Dividend Stocks for Income Investors

Updated Category News Views 65

Dive into Dividend Investing Dividend investing is often overlooked, especially in an era dominated by the latest advancements in technology and artificial intelligence. While the allure of tech growth may be tempting, savvy investors understand the enduring value of reliable income-generating stocks. The world of dividend stocks is vast, and their potential for...

Continue Reading